RhumbLine Advisers
APGE

RhumbLine Advisers’s Apogee Therapeutics APGE Stock Holding History

RhumbLine Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51M Buy
56,616
+7,938
+16% +$715K 0.01% 1251
2026
Q1 		$4.1M Buy
48,678
+2,707
+6% +$197K ﹤0.01% 1501
2025
Q4 		$3.47M Sell
45,971
-1,828
-4% -$115K ﹤0.01% 1590
2025
Q3 		$1.9M Sell
47,799
-1,417
-3% -$54.1K ﹤0.01% 1940
2025
Q2 		$2.14M Sell
49,216
-5,169
-10% -$197K ﹤0.01% 1848
2025
Q1 		$2.03M Buy
54,385
+1,665
+3% +$64.4K ﹤0.01% 1801
2024
Q4 		$2.39M Buy
52,720
+1,750
+3% +$89.2K ﹤0.01% 1789
2024
Q3 		$2.99M Buy
50,970
+1,535
+3% +$73.5K ﹤0.01% 1681
2024
Q2 		$1.95M Sell
49,435
-6,261
-11% -$304K ﹤0.01% 1900
2024
Q1 		$3.7M Buy
55,696
+28,468
+105% +$1.24M ﹤0.01% 1578
2023
Q4 		$761K Buy
27,228
+908
+3% +$18.2K ﹤0.01% 2419
2023
Q3 		$561K Buy
+26,320
New +$580K ﹤0.01% 2557

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

RhumbLine Advisers's APGE Position: Q2 2026 in Review

RhumbLine Advisers increased its Apogee Therapeutics (APGE) stake by 16% in Q2 2026, buying an estimated $715K and bringing the position to 56,616 shares worth $7.51M. The position accounts for 0.01% of the portfolio, ranked #1251.

RhumbLine Advisers first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • RhumbLine Advisers held 56,616 shares of Apogee Therapeutics worth $7.51M as of Q2 2026.
  • RhumbLine Advisers bought 7,938 Apogee Therapeutics shares in Q2 2026, an estimated $715K.
  • Apogee Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1251 holding.
  • RhumbLine Advisers first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.